Pharmacologic restoration of ΔF508 CFTR-mediated chloride current

Kidney International

Volumn 57, Issue 3, 2000, Pages 832-837

  Zeitlin, Pamela L ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Butyrates; Cystic fibrosis; Protein trafficking

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; CHAPERONE; TRANSMEMBRANE CONDUCTANCE REGULATOR;

CELL MEMBRANE; CHLORIDE CURRENT; CLINICAL TRIAL; CONFERENCE PAPER; CYSTIC FIBROSIS; ENDOPLASMIC RETICULUM; GENE EXPRESSION; GENOTYPE; HUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; TEMPERATURE SENSITIVITY;

EID: 0033936843     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2000.00922.x     Document Type: Conference Paper

References (44)

1. 1. RIORDAN JR, ROMMENS JM, KFREM B, ALON N, ROZMAHFL R, GRZELCZAK Z, ZIELENSKI J, LOK S, PLAVSIC N, CHOU JL: Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. Science 245:1066-1073, 1989 [published erratum appears in Science 245:1437, 1989]
2. 2. KOPITO RR: Biosynthesis and degradation of CFTR. Physiol Rev 79(Suppl):S167-S173, 1999
3. 3. DALEMANS W, BARBRY P, CHAMPIGNY G, JALLAT S, DOTI K, DREYER D, CRYSTAL RG, PAVIRANI A, LECOCQ JP, LAZDUNSKI M: Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation [see comments]. Nature 354:526-528, 1991
4. 4. PASYK EA, FOSKETI JK: Mutant (delta F508) cystic fibrosis transmembrane conductance regulator Cl channel is functional when retained in endoplasmic reticulum of mammalian cells. J Biol Chem 270:12347-12350, 1995
5. 5. HAWS CM, NEPOMUCENO IB, KROUSE ME, WAKELFE H, LAW T, XIA Y, NGUYEN H, WINE JJ: Delta F508-CFTR channels: Kinetics, activation by forskolin, and potentiation by xanthines. Am J Physiol 270:C1544-C1555, 1996
6. 6. LI C, RAMJEESINGH M, REYES E, JENSEN T, CHANG X, ROMMENS JM, BEAR CE: The cystic fibrosis mutation (delta F508) does not influence the chloride channel activity of CFTR. Nat Genet 3:311-316, 1993
7. 7. EGAN ME, SCHWEIBERT EM, GUGGINO WB: Differential expression of ORCC and CFTR induced by low temperature in CF airway epithelial cells. Am J Physiol 268(Cell Physiol 37):C243-C251, 1995
8. 8. BROWN CR, HONG-BROWN LQ, WELCH WJ: Correcting temperature-sensitive protein folding defects. J Clin Invest 99:1432-1444, 1997
9. 9. JENSEN TJ, LOO MA, PIND S, WILLIAMS DB, GOLDBERG AL, RIORDAN JR: Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell 83:129-135, 1995
10. 10. WARD CL, KOPITO RR: Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild-type and mutant proteins. J Biol Chem 269:25710-25718, 1994
11. 11. WARD CL, OMURA S, KOPITO RR: Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 83:121-127, 1995
12. 12. DENNING GM, ANDERSON MP, AMARA JF, MARSHALL J, SMITH AE, WELSH MJ: Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive [see comments]. Nature 358:761-764, 1992
13. 13. KO YH, THOMAS PJ, DELANNOY MR, PEDERSEN PL: The cystic fibrosis transmembrane conductance regulator. Overexpression, purification, and characterization of wild type and delta F508 mutant forms of the first nucleotide binding fold in fusion with the maltose-binding protein. J Biol Chem 268:24330-24338, 1993
14. 14. TAMARAPPOO BK, VERKMAN AS: Defective aquaporin-2 trafficking in nephrogenic diabetes insipidus and correction by chemical chaperones. J Clin Invest 101:2257-2267, 1999
15. 15. BROWN CR, HONG-BROWN LQ, WELCH WJ: Strategies for correcting the delta F508 CFTR protein-folding defect. J Bioenerg Biomembr 29:491-502, 1997
16. 16. CANDIDO EP, REEVES R, DAVIE JR: Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 14:105-113, 1978
17. 17. MCGRATH SA, BASU A, ZEITLIN PL: Cystic fibrosis gene and protein expression during fetal lung development. Am J Respir Cell Mol Biol 8:201-208, 1993
18. 18. HARRIS A, CHALKLEY G, GOODMAN S, COLEMAN L: Expression of the cystic fibrosis gene in human development. Development 113:305-310, 1991
19. 19. CHENG SH, FANG SL, ZABNER J, MARSHALL J, PIRAINO S, SCHIAVI SC, JEFFERSON DM, WELSH MJ, SMITH AE: Functional activation of the cystic fibrosis trafficking mutant delta F508-CFTR by overexpression. Am J Physiol 268:L615-L624, 1995
20. 20. RUBENSTEIN RC, EGAN ME, ZEITLIN PL: In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J Clin Invest 100:2457-2465, 1997
21. 21. YANG Y, JANICH S, COHN JA, WILSON JM: The common variant of cystic fibrosis transmembrane conductance regulator is recognised by hsp70 and degraded in a pre-Golgi nonlysosomal compartment. Proc Natl Acad Sci USA 90:9480-9484, 1993
22. 22. PIND S, RIORDAN JR, WILLIAMS DB: Participation of the endoplasmic reticulum chaperone calnexin (p88, IP90) in the biogenesis of the cystic fibrosis transmembrane conductance regulator. J Biol Chem 269:12784-12788, 1994
23. 23. STRICKLAND E, QU BH, MILLEN L, THOMAS PJ: The molecular chaperone hsc70 assists the in vitro folding of the N-terminal nucleotide-binding domain of the cystic fibrosis transmembrane conductance regulator. J Biol Chem 272:25421-25424, 1997
24. 24. MEACHAM GC, LU Z, KING S, SORSCHER E, TOUSSON A, D'AMORE-BRUNO M: The Hdf-2/Hsc70 chaperone pair facilitates early steps in CFTR biogenesis. EMBO J 18:1492-1505, 1999
25. 25. RUBENSTEIN RC, ZEITLIN PL: A pilot clinical trial of sodium 4-phenylbutyrate (Buphenyl) in delta F508-homozygous cystic fibrosis patients: Evidence of restoration of nasal epithelial CFTR function. Am J Resp Crit Care Med 157:484-490, 1998
26. 26. COLLINS AF, PEARSON HA, GIARDINA P, MCDONAGH KT, BRUSILOW SW, DOVER GJ: Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: A clinical trial. Blood 85:43-49, 1995
27. 27. SHER GD, GINDER GD, LITTLE J, YANG S, DOVER GJ, OLIVIERI NF: Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies [see comments]. N Engl J Med 332:1606-1610, 1995
28. 28. KEMP S, WEI HM, LU JF, BRAITERMAN LT, MCGUINNESS MC, MOSER AB, WATKINS PA, SMITH KD: Gene redundancy and pharmacological gene therapy: Implications for X-linked adrenoleukodystrophy [see comments]. Nat Med 4:1261-1268, 1998
29. 29. CARDUCCI M, BOWLING M, EISENBERGER M, SINIBALDI V, SIMONS J, CHEN T, NOE D, GROCHOW L, DONEHOWER R: Phenylbutyrate (PB) for refractory solid tumors: A phase I clinical and pharmacological evaluation. Proc AACR 39:506-506, 1998
30. 30. JIANG C, FANG SL, XIAO YF, O'CONNOR SP, NADLER SG, LEE DW, JEFFERSON DM, KAPLAN JM, SMITH AE, CHENG SH: Partial restoration of cAMP-stimulaled CFTR chloride channel activity in DeltaF508 cells by deoxyspergualin. Am J Physiol 275:C171-C178, 1998
31. 31. COHEN BE, LEE G, JACOBSON KA, KIM YC, HUANG Z, SORSCHER EJ, POLLARD HB: 8-cyclopentyl-1,3-dipropylxanthine and other xanthines differentially bind to the wild-type and delta F508 first nucleotide binding fold (NBF-1) domains of the cystic fibrosis transmembrane conductance regulator. Biochemistry 36:6455-6461, 1997
32. 32. GUAY-BRODER C, JACOBSON KA, BARNOY S, CABANTCHIK ZI, GUGGINO WB, ZEITLIN PL, TURNER RJ, VERGARA L, EIDELMAN O, POLLARD HB: A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine selectively activates chloride efflux from human epithelial and mouse fibroblast cell lines expressing the cystic fibrosis transmembrane regulator delta F508 mutation. Biochemistry 34:9079-9087, 1995
33. 33. ARISPE N, MA J, JACOBSON KA, POLLARD HB: Direct activation of cystic fibrosis transmembrane conductance regulator channels by 8-Cyclopentyl-1,3-dipropylxanthine (CPX) and 1,3-Diallyl-8-cyclohexylzanthine (DAX). J Biol Chem 273:5727-5734, 1997
34. 34. FISCHER H, ILLEK B, MACHEN TE: Regulation of CFTR by protein phosphatase 2B and protein kinase C. Pflügers Arch 436:175-181, 1998
35. 35. HE Z, RAMAN S, GUO Y, REENSTRA W: Cystic fibrosis transmembrane conductance regulator activation by cAMP-independent mechanisms. Am J Physiol 275(Cell Physiol):958-966, 1998
36. 36. WEINREICH F, WOOD PG, RIORDAN JR, NAGEL G: Direct action of genistein on CFTR. Pflügers Arch 434:484-491, 1997
37. 37. JANSSEN K, MENSINK RP, COX FJ, HARRYVAN JL, HOVENIER R, HOLLMAN PC, KATAN MB: Effects of the flavonoids quercetin and apigenin on hemostasis in healthy volunteers: Results from an in vitro and a dietary supplement study. Am J Clin Nutr 67:255-262, 1998
38. 38. ILLEK B, FISCHER H: Flavonoids stimulate Cl conductance of human airway epithelium in vitro and in vivo. Am J Physiol 275:L902-L910, 1998
39. 39. HWANG TC, WANG F, YANG IC, REENSTRA WW: Genistein potentiates wild-type and delta F508-CFTR channel activity. Am J Physiol 273:C988-C998, 1997
40. 40. SMITH SN, DELANEY SJ, DORIN JR, PARLEY R, GEDDES DM, PORTEOUS DJ, WAINWRIGHT BJ, ALTON EW: Effect of IBMX and alkaline phosphatase inhibitors on Cl secretion in G551D cystic fibrosis mutant mice. Am J Physiol 274:C492-C499, 1998
41. 41. HOWARD M, FRIZZELL RA, BEDWELL DM: Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations [see comments]. Nat Med 2:467-469, 1996
42. 42. SHOSHANI T, KEREM E, SZEINBERG A, AUGARTEN A, YAHAV Y, COHEN D, RIVLIN J, TAL A, KEREM B: Similar levels of mRNA from the W1282X and the delta F508 cystic fibrosis alleles, in nasal epithelial cells. J Clin Invest 93:1502-1507, 1994
43. 43. BEDWELL DM, KAENJAK A, KEELING K, MANOUVAKHOVA M, ZSUZSA B, BENOS D, BUBIEN JK, SCHWIEBERT EM, CLANCY JP, RUIZ F, SORSCHER EJ: Aminoglycoside repair of premature translation termination mutations. Pediatric Pulmonol S 17:168-168, 1998
44. 44. DRUMM ML, STEAGALL WK, KELLEY TJ, MILGRAM LJ, KONSTAN MW: Phosphodiesterase inhibitor-stimulated chloride secretion from gut and respiratory epithelia. Pediatric Pulmonol S 17:168-169, 1998